Sodium glycerophosphate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Aparna Vuppala (talk | contribs)
nocaptcha, Administrators
6,313 edits
Created page with "{{DrugProjectFormSinglePage |authorTag= <!--Overview--> |genericName= |aOrAn= a |drugClass= |indication= |hasBlackBoxWarning= Yes |adverseReactions= <!--Bla..."
 
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Sodium glycerophosphate": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(6 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=
|authorTag={{AV}}
 
|genericName=sodium glycerophosphate
 
|aOrAn=a
<!--Overview-->
|drugClass=[[potassium supplement]]
 
|indicationType=prophylaxis
|genericName=
|indication=adult patients and infants as a supplement in intravenous [[nutrition]] to meet the requirements of [[phosphate]]
 
|adverseReactions=absence of drug reaction<!--Black Box Warning-->
 
|blackBoxWarningTitle=Title
 
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|aOrAn=
 
a
 
|drugClass=
 
 
 
|indication=
 
 
 
|hasBlackBoxWarning=
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
* Content
Line 42: Line 15:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=*Sodium glycerophosphate  is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of [[phosphate]].
|fdaLIADAdult=
 
*Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.
====Posology and method of administration====
====Posology and method of administration====
*Glycophos must not be given undiluted.
*Sodium glycerophosphate must not be given undiluted.


=====Adults:=====
=====Adults:=====
*The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of Glycophos added to the infusion solution or to the admixture for which compatibility has been proved.
*The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of sodium glycerophosphate added to the infusion solution or to the admixture for which compatibility has been proved.


<!--Off-Label Use and Dosage (Adult)-->
<!--Off-Label Use and Dosage (Adult)-->


<!--Guideline-Supported Use (Adult)-->
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=*sodium glycerophosphate is indicated in adult patients and infants as a supplement in intravenous [[nutrition]] to meet the requirements of [[phosphate]].
|fdaLIADPed=
*Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.
====Posology and method of administration====
====Posology and method of administration====
*Glycophos must not be given undiluted.
*Sodium glycerophosphate must not be given undiluted.
=====Infants:=====
=====Infants:=====
*The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.
*The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.
Line 83: Line 41:


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=
 
 
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
 
|contraindications=*sodium glycerophosphate should not be given to patients in a state of dehydration or with [[hypernatraemia]], [[hyperphosphataemia]], severe [[renal insufficiency]] or [[shock]].
|contraindications=
 
* Condition1


<!--Warnings-->
<!--Warnings-->
|warnings=* sodium glycerophosphate should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.


|warnings=
sodium glycerophosphate must not be given undiluted.
 
* Glycophos should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.
 
Glycophos must not be given undiluted.


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
 
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
 


<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
 
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
 


<!--Drug Interactions-->
<!--Drug Interactions-->
 
|drugInteractions=*No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
<!--Use in Specific Populations-->
|useInPregnancyFDA=*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.


|useInPregnancyFDA=
*No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.
*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when Glycophos is administered during pregnancy.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPregnancyAUS=
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[renal impairment]].
 
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with [[hepatic impairment.]]
|useInLaborDelivery=
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are [[immunocompromised]].
 
|useInNursing=
*Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Glycophos. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.
 
*No adverse events are to be expected when Glycophos is administered during pregnancy.
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
 
|administration=* Intravenous
|administration=
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
 
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.


<!--Overdosage-->
<!--Overdosage-->
 
|overdose=*No adverse effects of an overdose have been reported. Most patients in need of intravenous [[nutrition]] have an increased capacity to handle glycerophosphate.  
|overdose=
 
*No adverse effects of an overdose have been reported. Most patients in need of intravenous nutrition have an increased capacity to handle glycerophosphate.  


<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
 
|drugBox=<!--Mechanism of Action-->
|drugBox=
|mechAction=<!--Structure-->
 
|structure=* The active ingredient in 1 ml of sodium glycerophosphate correspond to
 
:*Phosphate        1 mmol
 
:*Sodium            2 mmol
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*  
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
 
|PD=*Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.
|PD=
 
*Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.
<!--Pharmacokinetics-->
<!--Pharmacokinetics-->
|PK=*To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all [[hydrolysis]] of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.


|PK=
*No pharmacokinetical data is available for infants, however with the recommended dosage [[hyperphosphataemia]] is unlikely.
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


*To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


*No pharmacokinetical data is available for infants, however with the recommended dosage hyperphosphataemia is unlikely.
<!--How Supplied-->
<!--Nonclinical Toxicology-->
|howSupplied=*sodium glycerophosphate may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.


|nonClinToxic=
*Shelf life is 3 years


There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
*Special precautions for storage


<!--Clinical Studies-->
:*Do not store above 25°C. Do not freeze.


|clinicalStudies=
:*Nature and contents of container


There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
:8Polypropylene vial.


<!--How Supplied-->
:*Pack size: 10 x 20 ml


|howSupplied=
*Instructions for use/handling


*  
:*sodium glycerophosphate must not be given undiluted.


<!--Patient Counseling Information-->
<!--Patient Counseling Information-->
 
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


<!--Precautions with Alcohol-->
<!--Precautions with Alcohol-->
 
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


<!--Brand Names-->
<!--Brand Names-->
 
|brandNames=*Glycophos
|brandNames=
 
* ®<ref>{{Cite web | title =  | url =  }}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
 
|lookAlike=<!--Drug Shortage Status-->
|lookAlike=
 
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
 
|drugShortage=
|drugShortage=
}}
}}
<!--Pill Image-->
<!--Pill Image-->


<!--Label Display Image-->
<!--Label Display Image-->
 
{{LabelImage
|fileName={{PAGENAME}}01.png|This image is provided by the National Library of Medicine.
}}
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}02.png|This image is provided by the National Library of Medicine.
|fileName={{PAGENAME}}02.png|This image is provided by the National Library of Medicine.

Latest revision as of 17:09, 20 August 2015

Sodium glycerophosphate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sodium glycerophosphate is a potassium supplement that is FDA approved for the prophylaxis of adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. Common adverse reactions include absence of drug reaction.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Sodium glycerophosphate is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

Posology and method of administration

  • Sodium glycerophosphate must not be given undiluted.
Adults:
  • The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of sodium glycerophosphate added to the infusion solution or to the admixture for which compatibility has been proved.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium glycerophosphate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • sodium glycerophosphate is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

Posology and method of administration

  • Sodium glycerophosphate must not be given undiluted.
Infants:
  • The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sodium glycerophosphate in pediatric patients.

Contraindications

Warnings

  • sodium glycerophosphate should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.

sodium glycerophosphate must not be given undiluted.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Sodium glycerophosphate in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Sodium glycerophosphate in the drug label.

Drug Interactions

  • No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sodium glycerophosphate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sodium glycerophosphate during labor and delivery.

Nursing Mothers

  • Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.
  • No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.

Pediatric Use

There is no FDA guidance on the use of Sodium glycerophosphate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Sodium glycerophosphate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sodium glycerophosphate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sodium glycerophosphate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sodium glycerophosphate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sodium glycerophosphate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Intravenous

Monitoring

There is limited information regarding Monitoring of Sodium glycerophosphate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Sodium glycerophosphate in the drug label.

Overdosage

  • No adverse effects of an overdose have been reported. Most patients in need of intravenous nutrition have an increased capacity to handle glycerophosphate.

Pharmacology

There is limited information regarding Sodium glycerophosphate Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Sodium glycerophosphate Mechanism of Action in the drug label.

Structure

  • The active ingredient in 1 ml of sodium glycerophosphate correspond to
  • Phosphate 1 mmol
  • Sodium 2 mmol

Pharmacodynamics

  • Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.

Pharmacokinetics

  • To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
  • No pharmacokinetical data is available for infants, however with the recommended dosage hyperphosphataemia is unlikely.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Sodium glycerophosphate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Sodium glycerophosphate in the drug label.

How Supplied

  • sodium glycerophosphate may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.
  • Shelf life is 3 years
  • Special precautions for storage
  • Do not store above 25°C. Do not freeze.
  • Nature and contents of container
8Polypropylene vial.
  • Pack size: 10 x 20 ml
  • Instructions for use/handling
  • sodium glycerophosphate must not be given undiluted.

Storage

There is limited information regarding Sodium glycerophosphate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sodium glycerophosphate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sodium glycerophosphate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Sodium glycerophosphate in the drug label.

Precautions with Alcohol

  • Alcohol-Sodium glycerophosphate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Glycophos

Look-Alike Drug Names

There is limited information regarding Sodium glycerophosphate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.


{{#subobject: 

 |Label Page=Sodium glycerophosphate
 |Label Name=Sodium glycerophosphate01.png

}}

{{#subobject: 

 |Label Page=Sodium glycerophosphate
 |Label Name=Sodium glycerophosphate02.png

}}


{{#subobject: 

 |Label Page=Sodium glycerophosphate
 |Label Name=Sodium glycerophosphate03.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Sodium_glycerophosphate&oldid=1137555"